James Shen is an Oncology physician.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
301 W Huntington Dr
Arcadia, CA 910073462
Telephone
626-218-9840Provider last certified this registry record 11 Nov 2020.
Industry payments
16 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Dendreon Pharmaceuticals LLCProgram year20251 payment
- Novartis Pharmaceuticals CorporationProgram year20252 payments
- SOBI, INCProgram year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
49.8%PD-1 inhibitor23.5%Nivolumab51%Pembrolizumab49%Part B, office-administered≥18 patientsPlatinum-based Drug16%Oxaliplatin98%Carboplatin2%Part B, office-administered≥21 patients+ 13 more classes in this area
Metabolism & gastrointestinal
22.4%Substance P/Neurokinin-1 Receptor Antagonist18.1%Aprepitant100%Part B, office-administered≥54 patientsSerotonin-3 Receptor Antagonist2.6%Ondansetron hydrochloride96%Ondansetron Hcl3%Ondansetron Odt1%Part D + Part B≥73 patients+ 8 more classes in this area
Blood & clotting
14%Iron, parenteral preparations14%Ferric carboxymaltose100%Part B, office-administered≥11 patientsFactor Xa inhibitor0.1%Eliquis66%Xarelto35%Part D<11 patients+ 2 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”